BioVie Inc. (BIVI): Price and Financial Metrics


BioVie Inc. (BIVI): $2.64

0.10 (+3.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIVI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BIVI Stock Price Chart Interactive Chart >

Price chart for BIVI

BIVI Price/Volume Stats

Current price $2.64 52-week high $19.10
Prev. close $2.54 52-week low $2.50
Day low $2.55 Volume 20,400
Day high $2.70 Avg. volume 44,247
50-day MA $3.78 Dividend yield N/A
200-day MA $5.03 Market Cap 65.96M

BioVie Inc. (BIVI) Company Bio


BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.


BIVI Latest News Stream


Event/Time News Detail
Loading, please wait...

BIVI Latest Social Stream


Loading social stream, please wait...

View Full BIVI Social Stream

Latest BIVI News From Around the Web

Below are the latest news stories about Biovie Inc that investors may wish to consider to help them evaluate BIVI as an investment opportunity.

BioVie begins treatment in phase 2 trial of NE3107 for Parkinson''s disease

BioVie (BIVI) treated the first patient in a phase 2 trial assessing the potential pro-motoric impact of NE3107 in patients with Parkinsons disease

Seeking Alpha | January 20, 2022

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients. The NM201 study (NCT05083260) is a double-blind, placebo

Yahoo | January 20, 2022

Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?

Here is how Biocept, Inc. (BIOC) and BioVie Inc. (BIVI) have performed compared to their sector so far this year.

Yahoo | January 7, 2022

BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in a panel and in one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022. Details on the panel can be found bel

Yahoo | December 28, 2021

BioVie Announces Partnership with the American Liver Foundation

Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVies Phase 2b Study of BIV201 for Refractory Ascites Campaign to Improve Education on Ascites Due to Liver Cirrhosis and Raise Awareness of BioVies Phase 2b Study of BIV201 for Refractory Ascites

Intrado Digital Media | December 9, 2021

Read More 'BIVI' Stories Here

BIVI Price Returns

1-mo -31.43%
3-mo -19.51%
6-mo -60.00%
1-year -80.80%
3-year -78.88%
5-year -91.13%
YTD -41.33%
2021 -74.02%
2020 394.86%
2019 N/A
2018 0.00%
2017 -49.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4478 seconds.